151 patents currently held
728 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
8 more records may belong here and await a decision; they are not counted.
The next term ends in Mar 2027. from the record
Of the 728 now held by other companies, 553 are held via Hoffmann la Roche Inc., and 175 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
35
Ending by 2030
Mar 2027
Next term end
134
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2030 · High confidence
Also notable
Ends Mar 2035 · High confidence
Also notable
Ends Sep 2035 · High confidence
ANTI-PD-L1 Antibodies, Compositions and Articles of Manufacture
US 8,217,149
The most cited patent in this portfolio, cited by 583 later US patents, top 1% of utility patents granted in 2012 in our data. Protection runs to 2030.
Production of Heteromultimeric Proteins
US 9,637,557
Cited by 183 later US patents, top 5% of utility patents granted in 2017 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
METHODS OF TREATING INFLAMMATORY BOWEL DISEASE USING IL-22 Fc FUSION PROTEINS
US 10,160,793
Cited by 29 later US patents, top 10% of utility patents granted in 2018 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2035.
Formerly held, still cited
Notable
Ends Sep 2035 · High confidence
Cited by 91 later US patents, top 5% of utility patents granted in 2018 in our data, and renewed at every maintenance window due so far. Protection runs to 2035.
held via Hoffmann-La Roche Inc.
Also notable
Ends Dec 2036 · High confidence
Cited by 53 later US patents, top 5% of utility patents granted in 2021 in our data. Protection runs to 2036.
held via Hoffmann-La Roche Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 3 fees due Dec 9 to 25, 2026 · next Dec 9
- 3 fees due Jan 21 to 28, 2027 · next Jan 21
- 3 fees due Feb 11 to 20, 2027 · next Feb 11
- 2 fees due Mar 5 to 19, 2027 · next Mar 5
- 2 fees due May 5 to 19, 2027 · next May 5
- 2 fees due Jun 1, 2027
- 4 fees due Jul 5 to 23, 2027 · next Jul 5
- 1 fee due Sep 10, 2027The maintenance fee for Methods of Making and Using Multispecific Antibody Panels and Antibody Analog Panels (US 10,584,181) comes due Sep 10, 2027. Unpaid by Mar 10, 2028, it lapses early.
- 1 fee due Nov 3, 2027The maintenance fee for Cyclic Ether PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE Compounds and Methods of Use (US 9,328,106) comes due Nov 3, 2027. Unpaid by May 3, 2028, it lapses early.
Recent changes
- 33 of the patents on this record were granted since Aug 16, 2026
- 25 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 134 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Camelid Single-Domain Antibody Directed Against Phosphorylated Tau Proteins and Methods for Producing Conjugates Thereof | 3 in force | to Jan 2035 |
| Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use | 3 in force | to Apr 2028 |
| Package Leaflet | 2 in force | to Nov 2040 |
| Synthesis of Labeled Imidazo[1,2-a]pyrimidines | 2 in force | to May 2040 |
| COMPOSITION COMPRISING RECOMBINANT GpIba RECEPTOR PROTEIN | 2 in force | to Feb 2039 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US D678,998 | Medical Dispensing Device In force · High confidence | In force | High confidence | |
| US 7,867,452 | Multi-Well Filtration Device In force · High confidence | In force | High confidence | |
| US 7,438,861 | Heatable Pipette In force · High confidence | In force | High confidence | |
| US 8,324,206 | Pharmaceutical Compounds In force · Medium confidence | In force | Medium confidence | |
| US 8,383,620 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,993,563 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use held by Genentech, Inc. and F. Hoffmann-La Roche AG In force · High confidence | In force | High confidence | |
| US 7,888,352 | Phosphoinositide 3-Kinase Inhibitor Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,158,626 | Thiazolopyrimidine PI3K Inhibitor Compounds and Methods of Use In force · High confidence | In force | High confidence | |
| US 8,802,670 | Pharmaceutical compounds In force · Medium confidence | In force | Medium confidence | |
| US 7,781,433 | Pharmaceutical Compounds In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 151: 728 patents in force now held by others · 1,127 patents ended · 415 applications pending · 968 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.